Article
Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum
Registro en:
SMEATON, Laura M et al. Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum. The Journal of Infectious Diseases, v. 222, n. 1, p. 31-40, 2020.
0022-1899
10.1093/infdis/jiaa213
Autor
Smeaton, Laura M.
Kileel, Emma M.
Grinsztejn, Beatriz
Gardner, Edward M.
Starr, Kate
Murry, Melissa L.
Desvigne-Nickens, Patrice
Alston-Smith, Beverly
Waclawiw, Myron A.
Cooper-Arnold, Katharine
Madruga, José V.
Sangle, Shashi
Fitch, Kathleen V.
Zanni, Markella V.
Douglas, Pamela S.
Ribaudo, Heather J.
Grinspoon, Steven K.
Klingman, Karin L.
Resumen
Because persons who identify across the transgender spectrum (PATS) are a key population in human immunodeficiency virus (HIV) yet are underreported in HIV and cardiovascular research, we aimed to characterize this population within the REPRIEVE global clinical trial (n = 7770). Acceptance of gathering gender identity was high (96%). Participation by PATS was 1.7% overall, 2.4% among natal males, 0.3% among natal females, and varied across geographic regions (from 0% in sub-Saharan Africa to 2.3% in High Income Region). Thirty percent of natal male PATS identified other than transgender. Some characteristics differed by gender. Most notably, 38% of natal male PATS receiving gender-affirming treatment had waist circumference >102 cm (compared with ≤25% in other groups). Given that PATS is a key population, HIV research should routinely report trial participation and outcomes by gender in addition to natal sex, to provide the results needed to optimize medical care to PATS. 2050-01-01